Previous 10 | Next 10 |
home / stock / cytk / cytk articles
SOUTH SAN FRANCISCO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) announced that the Company will host the ...
SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced five presentations relat...
Statistically Significant and Clinically Meaningful Improvements Observed in Primary Efficacy Endpoint and All Secondary Endpoints; Results Consis...
SOUTH SAN FRANCISCO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced it will host an investo...
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to...
Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional...
Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 5 years by 40.29% on an annualized basis producing an average annual return of...
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced four presentations at t...
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the company is sch...
News, Short Squeeze, Breakout and More Instantly...
Cytokinetics Incorporated Company Name:
CYTK Stock Symbol:
NASDAQ Market:
Cytokinetics Incorporated Website:
2024-06-20 20:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 study evaluating the pharmacokinetics, safety and tolerability of aficamten in healthy Japanese and Caucasian parti...
2024-06-04 10:30:05 ET B. Riley analyst issues BUY recommendation for CYTK on June 4, 2024 08:58AM ET. The previous analyst recommendation was Buy. CYTK was trading at $49.018 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...